References
- Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289–93.
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
- Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27:295–300.
- Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics 2014;32:1093–104.
- Noyes K, Singer EA, Messing EM. Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors. Curr Opin Urol 2008;18:533–9.
- Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 2011;108:1119–23.
- Rambachan A, Matulewicz RS, Pilecki M, Kim JY, Kundu SD. Predictors of readmission following outpatient urological surgery. J Urol 2014;192:183–8.
- Readmission Reduction Program. Centers for Medicare and Medicaid Services 4 Aug. 2014; Web. 15 Mar. 2015. Available from: https://www.cms.gov/medicare/medicarefee-for-service-payment/acuteinpatientpps/readmissionsreduction-program.html [last accessed 11 July 2016].
- Kassin MT, Owen RM, Perez SD, Leeds I, Cox JC, Schnier K, et al. Risk factors for 30-day hospital readmission among general surgery patients. J Am Coll Surg 2012;215:322–30.
- Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009;360:1418–28.
- Mezei G, Chung F. Return hospital visits and hospital readmissions after ambulatory surgery. Ann Surg 1999;230:721–7.
- Valerio M, Cerantola Y, Fritschi U, Hubner M, Iglesias K, Legris AS, et al. Comorbidity and nutritional indices as predictors of morbidity after transurethral procedures: a prospective cohort study. Can Urol Assoc J 2014;8:E600–4.